Advice
In the absence of a submission from the holder of the marketing authorisation.
fondaparinux (Arixtra) is not recommended for use within NHS Scotland for the prevention of venous thromboembolic events (VTE) in medical patients who are judged to be at high risk of VTE and who are immobilised due to acute illness, such as cardiac insufficiency and/or acute respiratory disorders, and/or acute infections or inflammatory disease.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.
Download detailed advice29KB (PDF)
Medicine details
- Medicine name:
- fondaparinux (Arixtra)
- SMC ID:
- 261/06
- Indication:
- Prevention of venous thromboembolic events
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 May 2006